STOCK TITAN
  1. Home
  2. News
  3. ENVB

Enveric Biosciences Inc - ENVB STOCK NEWS

Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.

Enveric Biosciences Inc (ENVB) is a biotechnology innovator developing neuroplastogenic therapies for mental health disorders. This page serves as the definitive source for all company announcements, research milestones, and industry developments.

Access real-time updates on clinical trials, regulatory progress, and strategic partnerships. Investors will find curated press releases covering therapeutic advancements like EB-003's neuroplasticity mechanisms and EB-002's prodrug technology, alongside financial disclosures and executive insights.

Our news collection prioritizes accuracy and timeliness, offering:

• Clinical development updates
• Regulatory pathway announcements
• Peer-reviewed research highlights
• Strategic collaboration news

Bookmark this page for streamlined tracking of ENVB's progress in creating non-hallucinogenic psychiatric treatments. Verify information directly through primary sources via provided documentation links when available.

News

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

Rhea-AI Summary
Enveric Biosciences (ENVB) secures patents for novel neuroplastogenic small-molecule therapeutics to treat depression, anxiety, and addiction disorders. The company obtains U.S. Patent No. 11,918,594 for 'Multi-Substituent Psilocybin Derivatives' and anticipates U.S. Patent No. 11,931,338 for 'Nitrilated Psilocybin Derivatives'. These patents enhance Enveric's patent portfolio, providing composition of matter claim coverage for potential drug candidates and compounds in their PsybraryTM collections. The patents also strengthen partnerships and licensing opportunities, showcasing the company's commitment to developing proprietary products for mental health disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
none
-
News

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

Rhea-AI Summary
Enveric Biosciences (ENVB) signs three non-binding term sheets with an undisclosed biotechnology company for out-licensing of compounds, potentially leading to $200 million in milestone payments. The agreements entail exclusive global licenses for drug development, with royalty rates up to 10% on future sales. Enveric's extensive library of novel molecules aims to address mental health conditions, showcasing the value of its proprietary drug discovery platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
74.49%
Tags
none
-
News

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Rhea-AI Summary
Enveric Biosciences (NASDAQ: ENVB) announces the sale of a cancer-related patent portfolio to focus on developing neuroplastogenic small-molecule therapeutics for mental health disorders. The company will invest in lead candidates EB-003 and EB-002, targeting depression, anxiety, and addiction disorders. Enveric plans to continue research and development in this area while providing foundational patent protection for the undisclosed purchasers of the divested portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.29%
Tags
none
News

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

Rhea-AI Summary
Enveric Biosciences (ENVB) to initiate preclinical development of EB-003 in 2024 in preparation for IND submission
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
-
News

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market

Rhea-AI Summary
Enveric Biosciences (ENVB) announces agreements with holders of existing warrants to exercise at a reduced price, resulting in approximately $1.8 million in gross proceeds. The new warrants will allow for the purchase of up to 2,244,000 shares of common stock at an exercise price of $1.37 per share over a term of five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
none
-
News

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Rhea-AI Summary
Enveric Biosciences (ENVB) to initiate preclinical development of EB-003 in 2024 for IND submission
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.72%
Tags
none
News

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

Rhea-AI Summary
Enveric Biosciences (ENVB) Announces Positive Progress in GLP Safety and Toxicology Program for EB-373
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
clinical trial
-
News

Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”

Rhea-AI Summary
Enveric Biosciences (ENVB) to participate in Biotech Showcase 2024, presenting business and clinical development strategy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences
-
News

Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Rhea-AI Summary
Enveric Biosciences (ENVB) has identified three novel neuroplastic compounds from its EVM301 Series with the potential to offer a first-in-class approach to address difficult-to-treat disorders by promoting neuroplasticity without inducing hallucinations. The company plans to select one of the compounds for preclinical development early in 2024 in anticipation of Investigational New Drug (IND) application for a first-in-human clinical trial. Enveric’s research team successfully narrowed the EVM301 Series to three candidates with preclinical data indicating 5HT2A receptor binding, induction of neuroplasticity, and positive stress recovery outcomes in animal models showing no indication of hallucinations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
none
News

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives

Rhea-AI Summary
Enveric Biosciences (ENVB) has received a Notice of Allowance from the USPTO for a patent application pertaining to its EVM301 Series of molecules, aiming to develop treatments for mental health disorders. The company is focused on developing compounds that engage neurotransmitter receptors to promote neuroplasticity, with the goal of generating therapeutic benefit without inducing hallucinations. Enveric has filed multiple composition of matter patent applications with the USPTO, and to date, has received nine Notices of Allowance for patent applications claiming compounds in the EVM201 and EVM301 Series.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.44%
Tags
none
Stock ENVB logo
Enveric Biosciences Inc

Nasdaq:ENVB

ENVB Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ENVB Stock Data

2.89M
2.47M
0.07%
7.16%
64.5%
Biotechnology
Pharmaceutical Preparations
Link
United States
NAPLES